Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma.
10.3760/cma.j.cn112139-20220819-00361
- VernacularTitle:肝细胞癌免疫新辅助治疗的现状与挑战
- Author:
Yong Xiang XIA
1
;
Heng Song CAO
1
;
Wei Wei TANG
1
;
Xue Hao WANG
1
Author Information
1. Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,National Health Commission Key Laboratory of Living Donor Liver Transplantation,Nanjing Medical University,Nanjing 210000,China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Neoadjuvant Therapy;
Liver Neoplasms/pathology*;
Immunotherapy
- From:
Chinese Journal of Surgery
2023;61(1):7-12
- CountryChina
- Language:Chinese
-
Abstract:
With the development of modern liver surgical techniques and the progress of perioperative management,the survival rate after resection of hepatocellular carcinoma has been greatly improved,but the high recurrence and metastasis rate still limits the long-term survival after surgery. Preoperative neoadjuvant therapy has been confirmed to significantly reduce the postoperative recurrence rate and prolong survival in other types of cancer,but there has been a lack of effective systemic therapy for hepatocellular carcinoma for a long time,so the efficacy and regimen of neoadjuvant therapy for hepatocellular carcinoma are still controversial. PD-1/PD-L1 monoclonal antibody combined with anti-angiogenic targeted drugs has become a first-line regimen in systemic therapy for advanced hepatocellular carcinoma. This regimen has definite efficacy and high safety,bringing hope for neoadjuvant therapy of hepatocellular carcinoma. Recently,three clinical trials of neoadjuvant immunotherapy for hepatocellular carcinoma have been published internationally,which preliminarily suggest the efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma and lay a solid foundation for carrying out larger sample clinical studies in the future.
